INmune Bio, Inc. (NASDAQ:INMB – Get Rating) shares were up 2.5% on Friday . The stock traded as high as $7.78 and last traded at $7.36. Approximately 33,300 shares traded hands during mid-day trading, a decline of 38% from the average daily volume of 53,659 shares. The stock had previously closed at $7.18.
INmune Bio Price Performance
The company’s 50-day moving average price is $7.35 and its two-hundred day moving average price is $7.69. The company has a market cap of $132.08 million, a P/E ratio of -4.94 and a beta of 1.94. The company has a current ratio of 5.53, a quick ratio of 5.53 and a debt-to-equity ratio of 0.13.
INmune Bio (NASDAQ:INMB – Get Rating) last released its earnings results on Thursday, March 2nd. The company reported ($0.32) earnings per share for the quarter. The company had revenue of $0.10 million during the quarter. INmune Bio had a negative return on equity of 43.26% and a negative net margin of 10,816.06%.
Institutional Investors Weigh In On INmune Bio
About INmune Bio
INmune Bio, Inc Is a clinical stage biotechnology company, which engages in developing new immunotherapies that reprograms the immune system to fight cancer and Alzheimer’s disease. Its products include pipeline, INKMUNE-Cancer, INB03-Cancer, XPRO1595-Alzheimer and TRD, and LIVNate. The company was founded by Mark Lowdell in September 2015 and is headquartered in Boca Raton, FL.
- Get a free copy of the StockNews.com research report on INmune Bio (INMB)
- MarketBeat Week in Review – 5/15 – 5/19
- Applied Materials: Cracks In The Chip Recovery Or Time To Buy?
- Deere & Company Rallies On Farm Equipment Boom, Bullish Outlook
- How Many Roth IRAs Can You Have?
- Why You Should Consider Buying Nvidia Ahead Of Earnings
Receive News & Ratings for INmune Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for INmune Bio and related companies with MarketBeat.com's FREE daily email newsletter.